JP2022552152A5 - - Google Patents

Info

Publication number
JP2022552152A5
JP2022552152A5 JP2022520447A JP2022520447A JP2022552152A5 JP 2022552152 A5 JP2022552152 A5 JP 2022552152A5 JP 2022520447 A JP2022520447 A JP 2022520447A JP 2022520447 A JP2022520447 A JP 2022520447A JP 2022552152 A5 JP2022552152 A5 JP 2022552152A5
Authority
JP
Japan
Application number
JP2022520447A
Other languages
Japanese (ja)
Other versions
JP2022552152A (ja
JP7805289B2 (ja
JPWO2021067775A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/054036 external-priority patent/WO2021067775A1/en
Publication of JP2022552152A publication Critical patent/JP2022552152A/ja
Publication of JP2022552152A5 publication Critical patent/JP2022552152A5/ja
Publication of JPWO2021067775A5 publication Critical patent/JPWO2021067775A5/ja
Priority to JP2025010928A priority Critical patent/JP2025061811A/ja
Application granted granted Critical
Publication of JP7805289B2 publication Critical patent/JP7805289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022520447A 2019-10-02 2020-10-02 抗コネキシン抗体製剤 Active JP7805289B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025010928A JP2025061811A (ja) 2019-10-02 2025-01-24 抗コネキシン抗体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909267P 2019-10-02 2019-10-02
US62/909,267 2019-10-02
PCT/US2020/054036 WO2021067775A1 (en) 2019-10-02 2020-10-02 Anto-connexin antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025010928A Division JP2025061811A (ja) 2019-10-02 2025-01-24 抗コネキシン抗体製剤

Publications (4)

Publication Number Publication Date
JP2022552152A JP2022552152A (ja) 2022-12-15
JP2022552152A5 true JP2022552152A5 (https=) 2023-10-10
JPWO2021067775A5 JPWO2021067775A5 (https=) 2023-10-10
JP7805289B2 JP7805289B2 (ja) 2026-01-23

Family

ID=75273959

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520447A Active JP7805289B2 (ja) 2019-10-02 2020-10-02 抗コネキシン抗体製剤
JP2025010928A Pending JP2025061811A (ja) 2019-10-02 2025-01-24 抗コネキシン抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025010928A Pending JP2025061811A (ja) 2019-10-02 2025-01-24 抗コネキシン抗体製剤

Country Status (8)

Country Link
US (2) US12358981B2 (https=)
EP (1) EP4037703A4 (https=)
JP (2) JP7805289B2 (https=)
KR (1) KR20220113355A (https=)
CN (1) CN114786719A (https=)
AU (1) AU2020358101A1 (https=)
CA (1) CA3156812A1 (https=)
WO (1) WO2021067775A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
CN115825201B (zh) * 2022-07-28 2024-10-25 苏州凯劳生物科技有限公司 一种使用毛细管电泳仪电离还原蛋白二硫键并确定其自由巯基比例的方法
WO2025199516A1 (en) * 2024-03-22 2025-09-25 Board Of Regents, The University Of Texas System Compositions and methods for preserving or increasing lean muscle mass

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
CN1981054A (zh) * 2004-05-14 2007-06-13 加利福尼亚大学董事会 用抗wnt2单克隆抗体和sirna治疗癌症的方法
MX2010012324A (es) * 2008-05-15 2011-01-14 Biogen Idec Inc Anticuerpos anti-fn14 y usos de los mismos.
RU2408728C1 (ru) * 2009-07-28 2011-01-10 Федеральное государственное учреждение "Государственный Научный Центр Социальной и Судебной Психиатрии им. В.П. Сербского" (ФГУ "ГНЦССП Росздрава") Способ получения иммуногенного рекомбинантного экстраклеточного фрагмента коннексина-43
CA2806157C (en) 2010-07-26 2016-11-22 Les Laboratoires Servier Methods and compositions for liver cancer therapy
RU2457862C1 (ru) * 2011-07-07 2012-08-10 Федеральное государственное учреждение "Государственный научный центр социальной и судебной психиатрии им. В.П. Сербского" Министерства здравоохранения и социального развития Российской Федерации Способ лечения низкодифференцированных глиом
CN114621346B (zh) 2013-08-21 2025-06-10 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
IN2014MU01248A (https=) 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
CN107109410B (zh) 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
WO2017147561A1 (en) * 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3095897A1 (en) 2018-04-02 2019-10-10 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
US11427639B2 (en) * 2018-04-02 2022-08-30 Richter Gedeon Nyrt. Antibody-containing aqueous formulation and use thereof

Similar Documents

Publication Publication Date Title
JP2023537316A5 (https=)
JP2022552152A5 (https=)
CN306147045S (https=)
CN306137921S (https=)
CN305618998S (https=)
CN305756224S (https=)
CN305747547S (https=)
CN305640943S (https=)
CN305536787S (https=)
CN305535974S (https=)
CN305534668S (https=)
CN305533570S (https=)
CN305634697S (https=)
CN305531677S (https=)
CN305531022S (https=)
CN305530417S (https=)
CN305529638S (https=)
CN305529078S (https=)
CN305527655S (https=)
CN305526834S (https=)
CN305766112S (https=)
CN306152856S (https=)
CN306151337S (https=)
CN306150846S (https=)
CN306150334S (https=)